<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5731">
  <stage>Registered</stage>
  <submitdate>17/02/2015</submitdate>
  <approvaldate>17/02/2015</approvaldate>
  <nctid>NCT02400476</nctid>
  <trial_identification>
    <studytitle>A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide</studytitle>
    <scientifictitle>An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Intensive Loperamide Prophylaxis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PUMA-NER-6201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Early Stage HER2+ Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Neratinib
Treatment: drugs - Loperamide
Treatment: drugs - Budesonide
Treatment: drugs - Colestipol
Treatment: drugs - Bismuth Subsalicylate or Mesalamine

Experimental: neratinib, loperamide and budesonide - neratinib and intensive loperamide prophylaxis in combination with budesonide

Experimental: neratinib, loperamide and colestipol - neratinib and intensive loperamide prophylaxis in combination with colestipol

Experimental: neratinib, loperamide and bismuth subsalicylate or mesalamine - neratinib and intensive loperamide prophylaxis in combination with bismuth subsalicylate or mesalamine

Experimental: neratinib, loperamide - neratinib and intensive loperamide prophylaxis


Treatment: drugs: Neratinib
neratinib 240 mg (full treatment as extended adjuvant treatment for 13 cycles)

Treatment: drugs: Loperamide
intensive loperamide prophylaxis for two 28 day cycles (total 56 days) for neratinib and loperamide arm and budesonide arm, or 28 days for colestipol and bismuth subsalicylate or mesalamine arms

Treatment: drugs: Budesonide
budesonide extended release tablets 9 mg once daily with or without food for 28 days

Treatment: drugs: Colestipol
colestipol 2 g twice daily with or without food for 28 days

Treatment: drugs: Bismuth Subsalicylate or Mesalamine
bismuth subsalicylate 262 mg 3 times per day or mesalamine 2.4 g/day with food, for 28 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Grade 3 or higher diarrhea - The primary objective of this study is to characterize the incidence and severity of diarrhea in patients with early-stage HER2 overexpressed/amplified (HER2+) breast cancer treated with neratinib when administered with intensive loperamide prophylaxis, after prior treatment with trastuzumab.</outcome>
      <timepoint>Length of study (15 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and severity of diarrhea by loperamide exposure - Evaluate the association between loperamide exposure and the incidence and severity of diarrhea, with and without anti -inflammatory agents; with and without a bile acid sequestrant</outcome>
      <timepoint>Length of study (15 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of serious adverse events and other adverse events of special interest - Assess the incidence of serious adverse events (SAEs) and other adverse events of special interest (AESI)</outcome>
      <timepoint>Length of study (15 months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Aged =18 years at signing of informed consent

          2. Histologically confirmed stage 1 through stage 3c primary adenocarcinoma of the breast

          3. Documented HER2 overexpression or gene-amplified tumor by a validated approved method

          4. Patients must have completed a course of prior adjuvant trastuzumab or experienced
             side effects that resulted in early discontinuation of trastuzumab that have since
             resolved

          5. The last dose of trastuzumab must have been given &gt;2 weeks and =1 year (365 days) from
             enrollment

          6. Clinical and radiologic assessments that are negative for local or regional recurrence
             of disease or metastatic disease at the time of study entry, including

               -  Bone scan or positron emission tomography (PET) scan; required only if alkaline
                  phosphatase (ALP) is =2 x upper limit of normal (ULN) and/or there are symptoms
                  of metastatic bone disease. A confirmatory imaging study is required if the
                  results from the bone scan are questionable

               -  Computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound of the
                  abdomen and chest; required only if aspartate aminotransferase (AST)/alanine
                  aminotransferase (ALT) or ALP is =2 x ULN

               -  Chest radiograph

          7. Left ventricular ejection fraction (LVEF) =50% measured by multiple-gated acquisition
             scan (MUGA) or echocardiogram (ECHO)

          8. Eastern Cooperative Oncology Group (ECOG) status of 0 to 1

          9. Negative ß-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women
             of reproductive capacity (those who are biologically capable of having children) and
             for women less than 12 months after menopause. [Women are considered postmenopausal if
             they are =12 months without menses, in the absence of endocrine or anti-endocrine
             therapies.]

         10. Women of childbearing potential must agree and commit to the use of a highly effective
             non-hormonal method of contraception, ie, intrauterine device, bilateral tubal
             ligation, vasectomized partner, or abstinence (only when it is the preferred lifestyle
             of the patient), from the time of informed consent until 28 days after the last dose
             of the investigational products. Men and their female partners of childbearing
             potential must agree and commit to use a highly effective method of contraception (ie,
             any of the above methods or hormonal contraception associated with inhibition of
             ovulation) while on treatment and for 3 months after last dose of investigational
             products

         11. Recovery (ie, to Grade 1 or baseline) from all clinically significant AEs related to
             prior therapies (excluding alopecia, neuropathy, and nail changes)

         12. Provide written, informed consent to participate in the study and follow the study
             procedures</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Clinical or radiologic evidence of local or regional recurrence of disease or
             metastatic disease prior to or at the time of study entry

          2. Currently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for
             breast cancer

          3. Major surgery within &lt;30 days of starting treatment or received chemotherapy,
             investigational agents, or other cancer therapy, except hormonal therapy (eg,
             tamoxifen, aromatase inhibitors), &lt;14 days prior to the initiation of investigational
             products

          4. Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart
             failure (New York Heart Association functional classification of =2; including
             individuals who currently use digitalis, beta -blockers, or calcium channel blockers
             specifically for congestive heart failure), unstable angina, myocardial infarction
             within 12 months of enrollment, or ventricular arrhythmia

          5. QTc interval &gt;0.450 seconds (males) or &gt;0.470 (females), or known history of QTc
             prolongation or Torsade de Pointes (TdP)

          6. Screening laboratory assessments outside the following limits:

             Absolute neutrophil count (ANC) &lt;1,000/µl (&lt;1.0 x 109/L) Platelet count &lt;100,000/µl
             (&lt;100 x 109/L) Hemoglobin &lt;9 g/dL Total bilirubin &gt;1.5 x institutional upper limit of
             normal (ULN) (i n case of known Gilbert's syndrome, &lt;2 x ULN is allowed) Creatinine
             Creatinine clearance &lt;30 mL/min (as calculated by Cockcroft-Gault formula or
             Modification of Diet in Renal Disease [MDRD] formula)

          7. Active, unresolved infections

          8. Patients with a second malignancy, other than adequately treated non-melanoma skin
             cancers, in situ melanoma or in situ cervical cancer. Patients with other non-mammary
             malignancies must have been disease-free for at least 5years

          9. Currently pregnant or breast-feeding

         10. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg,
             Crohn's disease, malabsorption, or Grade =2 National Cancer Institute [NCI] Common
             Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any
             etiology at baseline)

         11. Clinically active infection with hepatitis B or hepatitis C virus

         12. Evidence of significant medical illness, abnormal laboratory finding, or psychiatric
             illness/social situations that could, in the Investigator's judgment, make the patient
             inappropriate for this study

         13. Known hypersensitivity to any component of the investigational products; known
             hypersensitivity to salicylates; known hypersensitivity to aspartame-containing
             products for patients with phenylketonuria; known allergies to any of the medications
             or components of medications used in the trial

         14. Unable or unwilling to swallow tablets</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,WA</recruitmentstate>
    <hospital>Sydney Adventist Hospital - Wahroonga</hospital>
    <hospital>Ashford Cancer Centre Research - Kurralta Park</hospital>
    <hospital>Calvary North Adelaide Hospital - North Adelaide</hospital>
    <hospital>BCRC-WA, Hollywood Private Hospital - Nedlands</hospital>
    <postcode> - Wahroonga</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Puma Biotechnology, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with
      Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02400476</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Puma Biotechnology, Inc.</name>
      <address />
      <phone>(424) 248-6500</phone>
      <fax />
      <email>clinicaltrials@pumabiotechnology.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>